Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 13/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086364 | 0.92 | CCNE1 (0.32) | CCNE2CCNE1CDK2KDM4ENPC1 | |
| SCHEMBL5082395 | 0.92 | CDK1 (0.35) | CCNE2CCNE1CDK2CDK1CCNB1 | |
| SCHEMBL5082380 | 0.90 | HPRT1 (0.38) | CCNE2CCNE1CDK2KDM4ENPC1 | |
| SCHEMBL5086347 | 0.88 | CCNE2 (0.32) | CCNE2CCNE1CDK2CDK1CCNB1 | |
| SCHEMBL5086060 | 0.86 | SERPINA3 (0.32) | CDK1CCNB1CDK5CDK5R1CCNB2 | |
| SCHEMBL5083005 | 0.85 | CCNB2 (0.30) | CDK1CCNB1CDK5CDK5R1CCNB2 | |
| SCHEMBL5080082 | 0.84 | CCNB2 (0.31) | CCNE2CCNE1CDK2CDK1CCNB1 | |
| SCHEMBL5082999 | 0.83 | HPRT1 (0.40) | CCNE2CCNE1CDK2CDK1CCNB1 | |
| SCHEMBL5080071 | 0.81 | CDK1 (0.31) | CDK1CCNB1 | |
| SCHEMBL5086113 | 0.81 | HPRT1 (0.35) | CCNE2CCNE1CDK2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | CCNE2 240/4885CCNE1 440/4885CDK2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.